65,437 trials
Safety and Tolerability
Primary: Number and % of Subjects Experiencing Adverse Events Following a Single Oral Dose of Fenretinide Under Fasted Conditions — 1; 2; 3; 2 Participants
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
Breast Cancer · Urothelial Carcinoma
Primary: Number of Participants With Dose-Limiting Toxicities at 3.2 mg/kg and 5.4 mg/kg Dose Level in Participants With HER2-expressing Advanced Breast Cancer in Dose Escalation…
Stroke, Acute · Ischemic Stroke · Hemorrhagic Stroke
Primary: Modified Rankin Scale at 3 Months in Acute Stroke (AIS and ICH) — 2; 1 units on a scale
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HRSD) — 12.32; 12.06; 20.20; 20.08 units on a scale — p=.016
Pulmonary Hypertension · Insomnia · Fatigue
Primary: Retention Rate — 0; 1; 2 Participants
Drug Drug Interaction
Primary: Plasma Pharmacokinetic (PK) Parameters of Givinostat, Following First Single-dose Administration of Givinostat: Cmax — 48.06; 7.34; 132.20; 88.77 ng/mL
Physical Activity
Primary: Change in Use of Movement Integration Strategies (Mean Per Day) — 0.4; 0.1; 0.8 Change in movement strategy use per day
Metastatic Breast Cancer
Primary: Area Under the Concentration Time Curve at Steady State (AUCss) — 34400; 31800 ug*h/mL
Advanced and Metastatic Solid Tumor
Primary: The Number of Dose Limiting Toxicity (DLT) for RD Determination — 0; 0; 3; 5 Participants
Cervical Cancer
Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants
Atrial Fibrillation
Primary: Interview Process — 34 Participants
Gulf War Illness
Primary: Change From Baseline in Overall Gulf War Illness Disease Severity — 13; 0; 8; -1 units on a scale
Glaucoma · Open Angle Glaucoma
Primary: Performance: Level of Agreement Between GAT and the ARGOS-SC System — 0.8; -0.2 mmHg
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1